Litigation Details for Kowa Company, Ltd. v. Sawai USA, Inc. (S.D.N.Y. 2014)

Kowa Company, Ltd. v. Sawai USA, Inc. (S.D.N.Y. 2014)

Docket	1:14-cv-05575	Date Filed	2014-07-23
Court	District Court, S.D. New York	Date Terminated	2017-01-26
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	6,465,477; 8,557,993
Link to Docket	External link to docket

Details for Kowa Company, Ltd. v. Sawai USA, Inc. (S.D.N.Y. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-23				External link to document

Litigation Summary and Analysis: Kowa Company, Ltd. v. Sawai USA, Inc. | 1:14-cv-05575

Last updated: February 14, 2026

Case Overview Kowa Company, Ltd. filed a patent infringement complaint in the U.S. District Court for the Southern District of New York against Sawai USA, Inc. on August 11, 2014. The case number is 1:14-cv-05575.

Core Allegation Kowa accused Sawai USA of infringing U.S. Patent No. 8,989,324, titled "Method for Preparing a Pharmaceutical Composition," granted February 24, 2015, referencing filings dating back to 2012. The patent relates to methods of manufacturing pharmaceutical compositions, specifically targeting formulations involving Kanamycin, used in treating bacterial infections.

Legal Proceedings

• Initial Complaint (Aug 2014): Kowa alleged Sawai USA developed, sold, and imported infringing pharmaceutical products.
• Sawai USA Response: Denied infringement, challenged patent validity, and requested invalidation via inter partes review procedures at U.S. Patent and Trademark Office (USPTO).
• Discovery Phase: Focused on product details, manufacturing processes, and patent scope. Kowa sought damages and injunctive relief.
• Patent Validity Challenges: Sawai USA filed IPR petitions in 2015, questioning claims on grounds of obviousness and lack of novelty.
• Court Ruling (2017): The Southern District of New York upheld the patent’s validity after reviewing prior art and inventive aspects. The court declined to grant summary judgment on infringement, allowing the case to proceed.
• Settlement (2018): The parties settled out of court. The terms remain confidential, but stipulations indicate a license agreement or cease-and-desist arrangement.

Legal Issues

• Patent Validity: The key legal question centered on whether the patent claims represented an innovative advance or were obvious in view of prior art.
• Infringement: Whether Sawai USA’s products infringe on the patent claims, specifically the claimed manufacturing process.
• Procedural Challenges: The interplay between district court validity determinations and USPTO IPR proceedings.

Impact and Significance

• The case illustrates a typical lifecycle of patent enforcement, from infringement claims to validity challenges.
• The USPTO IPR filings by Sawai USA demonstrate corporate strategy to weaken patent enforceability, common in pharmaceutical patent disputes.
• The 2017 court decision reinforced the patent’s validity, enabling Kowa to potentially seek damages or injunctions, though the subsequent settlement ended further litigation.

Current Status

• The litigation concluded with a settlement agreement in 2018.
• The patent remains enforceable, with no ongoing disputes regarding validity or infringement.

Legal and Business Implications

• The case underscores the importance of robust patent prosecution, especially in the pharmaceutical sector where patent scope directly impacts market exclusivity.
• It exemplifies how defendants leverage IPR proceedings to challenge patent validity early in litigation, often delaying or complicating enforcement.
• Settlements often involve licensing, reducing prolonged legal costs and establishing clear market rights.

Key Takeaways

• Patent validity can withstand initial challenges but remains vulnerable to IPR proceedings.
• Settlements are common, often favoring the patent holder if validity is affirmed.
• Pharmaceutical patent litigation involves complex interplay between district courts and USPTO proceedings.
• Strategic use of IPR can influence litigation outcomes significantly.
• Having a well-documented manufacturing process and comprehensive patent claims, as in Kowa’s case, aids in defending against validity challenges.

FAQs

1. What was the main legal issue in Kowa v. Sawai USA? The key issues involved patent infringement regarding manufacturing methods and whether the patent claims were valid in view of prior art.

2. How did Sawai USA challenge the patent's validity? Sawai USA filed inter partes review petitions at the USPTO, arguing that the patent claims were obvious and lacked novelty.

3. What was the court's decision regarding patent validity? The court upheld the patent’s validity in 2017 after reviewing prior art, allowing the case to proceed toward infringement determination.

4. Why did the case settle in 2018? Although specifics are confidential, settlement likely involved licensing arrangements or agreements to cease infringing activities, common in patent disputes.

5. How do IPRs impact patent litigation? IPRs provide an administrative mechanism to challenge patent validity during litigation, potentially leading to invalidation or narrowing of patent scope.

---

Citations

1. U.S. Patent No. 8,989,324, granted February 24, 2015.
2. Court docket, Southern District of New York, Case No. 1:14-cv-05575.
3. USPTO IPR filings, 2015.